GPX2 overexpression is involved in cell proliferation and prognosis of castration resistant prostate cancer

点击翻译按钮获取中文摘要

Prostate cancer generally acquires castration-resistant growth capacity with progression, resulting in resistance to anti-androgen therapy. Therefore, identification of genes that are regulated through this process may be important. We previously established a new castration-resistant prostate cancer (CRPC) metastatic model. We found that the glutathione peroxidase 2 (GPX2) gene was overexpressed in CRPC model, and we presented novel data showing that silencing of GPX2 by siRNA caused significant growth inhibition, and increased intracellular ROS in CRPC. Analyses of prostatectomy specimens demonstrated that GPX2 expression was significantly higher in residual cancer foci after hormone therapy than in hormone naive cancer foci. Moreover, patients with highly expressed GPX2 in biopsy specimen had significantly lower prostate-specific antigen recurrence-free survival and overall survival than those negative for GPX2. These findings suggest that GPX2 may be therapeutic target for CRPC.